Related Experiment Videos
Growth hormone therapy may increase fracture risk in a pubertal patient with osteogenesis imperfecta
Hiromasa Noda1, Hisashi Onishi, Kimiyuki Saitoh
1Department of Pediatrics, Funabashi Central Hospital, Chiba, Japan.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|March 5, 2002
Abstract:
We describe a patient with osteogenesis imperfecta type 1A who was treated with growth hormone for 9 years. The treatment resulted in a marked improvement in growth velocity, but four fractures occurred during the pubertal period.